DNA sequencing


Positional Sequencing: Barrett Bready of NABsys

Podcast Sponsor: DNAnexus- Unlocking the potential of DNA-based medicine and biotechnology with a collaborative and scalable DNA data management and analysis technology platform.

Guest:

Barett Bready, CEO, NABsys Bio and Contact Info

Listen (3:59) What brings you to DNA Sequencing?

Listen (3:33) Positional sequencing

Listen (4:13) Advantages

Listen (2:05) Is sequencing by hybridization sloppy?

Listen (4:20) How far along is the technology?

Listen (1:47) Market positioning?

Listen (4:25) Why Rhode Island?

Listen (4:00) What drives you personally?

Dr. Barret Bready is the CEO of NABsys, a company pursuing faster, higher quality sequencing technology for use in research and clinical care. The company is presenting their data for the first time at AGBT this year. Since joining NABsys, Barrett has been named one of the top "30 under 30" in New England by The Journal of New England Technology and 2011 Innovator of the Year in the state of Rhode Island.

BlueSEQ's Michael Heltzen

Podcast Sponsor: DNAnexus- Unlocking the potential of DNA-based medicine and biotechnology with a collaborative and scalable DNA data management and analysis technology platform.

Guest:

Michael Heltzen, CEO, BlueSEQ Bio and Contact Info

Listen (2:26) Why BlueSEQ?

Listen (5:20) How does the service work?

Listen (3:53) Platform agnostic

Listen (1:47) Who are the providers?

Listen (2:35) Thoughts on Roche action

Listen (2:22) Will you add bioinformatics?

Listen (1:54) Being an entrepreneur

Listen (5:03) Bio in Denmark

To wrap up our series on Sequencing and Genomic Medicine, we’d like to welcome Michael Heltzen. He’s the founder and CEO of BlueSEQ, a new start-up based in Arhus Denmark, serving as an online sequencing exchange, matching providers and researchers. Michael has served as Director of Partner Sales at CLC Bio, a bioinformatics company also based in Denmark and as VP at BGI Europe. Michael is a board member of both Startup City Denmark and the Copenhagenomics Foundation.

Sequencing: An Overview with Shawn Baker, BlueSEQ

Podcast Sponsor: DNAnexus- Unlocking the potential of DNA-based medicine and biotechnology with a collaborative and scalable DNA data management and analysis technology platform.

Guest:

Shawn Baker, Curator, BlueSEQ Bio and Contact Info

Listen (1:00) Curator at BlueSEQ

Listen (6:40) Roche's move on Illumina

Listen (4:44) Big news at JP Morgan 2012

Listen (1:47) Is speed really the issue?

Listen (2:35) Breakdown of market share

Listen (8:52) Advantages, disadvantages among major sequencers

Listen (9:58) Emerging Companies

Listen (1:17) AGBT

As we close out our series Sequencing and Genomic Medicine, we invited Shawn Baker, an advisor for sequencing technology at mendelspod, to join us and give an overview of the industry. He is the Curator for BlueSEQ's next generation sequencing Knowledge Bank. Having received his Ph.D. at the University of California, Davis, Shawn started his career as a Research Scientist at Illumina when it was a 15 person startup. Shawn is the founder of BiotechCareerCenter.com and a blogger at biotechmarketer.blogspot.com.

Our Take on Personalized Medicine World Conference 2012: The Road to Commercialization

This week we attended the <a href="http://pmwc2012.com" targe=_blank">Personalized Medicine World Conference 2012 in Mountain View, CA. Though sequencing continues to dominate the show, this year there was much more focus on the commercialization of existing technologies for better, more tailored health outcomes. Some news that came just after the conference gave a nice punctuation to the feeling that personalized medicine is here to stay.

Sequencing (of course)

Sequencing and Genomic Medicine with Cliff Reid, Complete Genomics

Podcast Sponsor: BioconferenceLive- Register for free to the upcoming Spring Conference on Laboratory Animal Science, February 15-16

Guest:

Cliff Reid, CEO, Complete Genomics Bio and Contact Info

Listen (2:20) Sequencing humans on both ends of life

Listen (4:08) Looking back at 2011

Listen (1:48) Business model validated

Listen (2:12) Partnership with DNAnexus

Listen (4:56) Standards too early a terrible thing for an industry

Listen (4:20) What happened with the stock?

Listen (6:26) Sequencing for the clinic

Listen (5:38) Path to $1000 genome

Listen (1:17) Plan in place to sequence millions of genomes

Listen (3:51) Personal path to DNA sequencing

Listen (7:05) Biggest challenge

Listen (2:08) Not a taker, but a maker of a revolution

Listen (1:00) Inspired by Churchill

Cliff Reid is the co-founder and CEO of Complete Genomics. The company sets itself apart by first, providing sequencing and data analysis as a service and second, by focusing exclusively on human DNA. Complete Genomics has announced several large scale partnerships this year, including one with Scripps Health for a “wellderly” study, looking at the DNA of healthy individuals with median age of 87 and with Inova Health systems to sequence the genomes of 500 babies and their parents. Cliff shares how he came to DNA sequencing and his thoughts on disruptive technologies. (Recorded Dec, 2011)

RS Sequencer with Hugh Martin, PacBio

Podcast Sponsor: Singulex- Watch our cardiovascular monitoring programs explained on YouTube

Guest:

Hugh Martin, former CEO, Pacific Biosciences Bio and Contact Info

Listen (1:45) Key events for 2011

Listen (9:05) RS Sequencer and its advantages

Listen (9:04) Disadvantages

Listen (:54) What happened to the stock?

Listen (2:30) Mike Hunkapiller joins team

Listen (6:16) What makes a good CEO?

Listen (2:17) How do you keep good people?

Listen (5:54) Fighting cancer personally

Listen (2:42) Clinical sequencing

Listen (3:50) Company direction

Listen (3:27) CSO Eric Schadt moves to NY

As part of our series, Sequencing and Genomic Medicine, I interviewed Hugh Martin of PacBio at the end of 2011. Personally, Hugh made headlines in 09 when he went public with his diagnosis of multiple myeloma. Previously, he served as CEO of ONI Systems—a high-speed optical telecommunications company he founded in 1998 and took public in 2000 and sold to Ciena in 2002 for $1 billion. Mr Martin led PacBio through an IPO and the commercial launch of their much anticipated RS Sequencer. On Jan 6 of 2012 it was announced that Mike Hunkapiller would step in as the new CEO. We hope to bring Mike to the program soon.

Ion Sequencing with Paul Billings, Life Tech

Podcast Sponsor: As the year takes off, we thank all our sponsors who have made mendelspod possible.

Affymetrix, Biotix, Epitomics, IDT, Ingenuity, Lab Roots, Laboratory Products Sales, Mo Bio, Science Exchange, Singulex, Traitwise

Guest:

Paul Billings, CMO, Life Technologies Bio and Contact Info

Listen (5:37) Ion type sequencing

Listen (3:33) Quality

Listen (4:33) Open source collaboration with customers

Listen (1:37) PCR in the age of sequencing

Listen (5:55) Advancing into clinical market

Listen (3:07) A transition period

Listen (2:18) Bioinformatics the bottleneck

Listen (4:36) Genomic Medicine Institute at El Camino Hospital

Listen (6:15) Were the doctors receptive?

Listen (5:10) Member of FDA committee

Listen (1:50) Why did you give up medical practice?

Listen (1:23) Why the fleece jacket?

Today we begin a Special Series entitled "Sequencing and Genomic Medicine." The series will include interviews with the leading companies in the genomic sequencing space. In all of the interviews I will ask about the application of sequencing into the clinic, exploring the promise of genomic medicine. Our first show is with Dr. Paul Billings, chief medical officer at Life Technologies.

This week at the JP Morgan conference in San Francisco, Life Technologies’ CEO, Greg Lucier, announced it is taking orders for a new benchtop sequencer, the Ion Proton. The upgrade to their Personal Genome Machine is said to sequence a human genome in 2 hours for $1,000. The $1000 genome has long been thought the benchmark for when sequencing would go into the clinic. The recent announcement of the proton makes our interview with Dr. Billings, recorded earlier, even more salient.

UPDATE: We talk with Paul from the CES about the Proton (1/11/12)



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup